Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
BJUI Compass|February 28, 2022
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinomaElio Adib, Talal El Zarif, Rohit K Jain, et al.
Clinical Genitourinary Cancer|May 20, 2021
Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial CarcinomaRohit K Jain, William Paul Skelton Iv, Gregory Russell Pond, et al.
Clinical Genitourinary Cancer|September 10, 2021
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotinCatherine Curran, Elio Adib, Vera Kazakova, et al.
Clinical Genitourinary Cancer|May 25, 2022
Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitorsPier Vitale Nuzzo, Elio Adib, Nicole Weise, et al.
European Urology|December 26, 2021
Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate RadiotherapyMatthew Mossanen, Filipe L F Carvalho, Vinayak Muralidhar, et al.
Clinical Genitourinary Cancer|May 19, 2021
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 InhibitorsGregory R Pond, Archana Agarwal, Moshe Ornstein, et al.
BMC Cancer|June 12, 2014
A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancerJemima J Dorairaj, David W Salzman, Deirdre Wall, et al.
Clinical Genitourinary Cancer|September 20, 2022
Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition SyndromesMatthew Mossanen, Amin H Nassar, Samantha M Stokes, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 18, 2019
Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinomaAmin H Nassar, Sarah Abou Alaiwi, Saud H AlDubayan, et al.
BJU International|April 28, 2021
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaborationPraful Ravi, Gregory R Pond, Leonidas N Diamantopoulos, et al.
Pageof 3